Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Overactive Bladder: full-pipeline trial registry
21 of 48 indexed Overactive Bladder trials are currently recruiting.
Corpus placement: #297 of 28,707 conditions by registered trial count.
48 US clinical trials · 21 currently recruiting · #297 of 28,707 conditions by registered trial count
Overactive Bladder: 48 US clinical trials tracked, 21 recruiting.
Overactive Bladder is the subject of 48 registered US clinical trials on ClinicalTrials.gov, 21 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Allergan, running 3 of these trials.
Enrollment posture brief
Registry condition overactive-bladder
OPEN 21 | RECR 44% | LATE 15 | EARLY 10 | RANK #297 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)
Overactive Bladder lists 21 open slots (44% of 48 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Overactive Bladder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Overactive Bladder is recruiting above its size-band peers.
21 of 48 indexed trials (43.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Overactive Bladder trials is spread across many organizations.
Allergan accounts for 3 of 48 trials (6.3%). 37 distinct sponsors appear on at least one study for this condition label.
-
Typical Overactive Bladder enrolment sits around 100 participants.
Median target enrolment is 100 among the 47 trials that report a genuine target (sentinel values excluded). 22 of those (46.8%) plan for fewer than 100 participants.
-
Overactive Bladder research is mostly interventional.
44 interventional and 4 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
48 total, page 1 of 1
Noninvasive Ultrasound Assessment of Detrusor Dysfunction
Mayo Clinic
NCT05652023
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
MedtronicNeuro
NCT05200923
TReating Incontinence for Underlying Mental and Physical Health
University of California, San Francisco
NCT05362292
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
InMode MD
NCT07209397
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
Valencia Technologies Corporation
NCT05685433
Antibiotic Usage Prior to OnabotulinumtoxinA Injection
Benaroya Research Institute
NCT04754737
Percutaneous Nerve Evaluation Trial Time
University of Chicago
NCT06226220
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
Walter Reed National Military Medical Center
NCT04020510
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
Corewell Health East
NCT04873037
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Axonics
NCT06511141
Bladder Botox UTI Antibiotic Prophylaxis
Walter Reed National Military Medical Center
NCT06387329
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Northwestern University
NCT05878951
Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement
Loma Linda University
NCT04527445
Yoga for Treatment of Overactive Bladder in Pediatric Patients
Duke University
NCT05895045
Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
Loyola University
NCT05557279
At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women
Oregon Health and Science University
NCT07178314
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
The Cleveland Clinic
NCT05799313
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
The Methodist Hospital Research Institute
NCT06072703
Add-On ZIDA Sock Therapy for Overactive Bladder
Medical University of South Carolina
NCT07432659
Predictive Utility and Mechanisms of Sacral Evoked Responses in Sacral Neuromodulation
University of Michigan
NCT06983470
rTMS in Overactive Bladder
The Methodist Hospital Research Institute
NCT06198439
Reduced-dose Botox for Urgency Incontinence Among Elder Females
Dartmouth-Hitchcock Medical Center
NCT05512039
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
Velicept Therapeutics
NCT03594058
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Allergan
NCT00910845
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
Astellas Pharma
NCT01093534
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
Novartis
NCT00171184
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Allergan
NCT01945489
Anticholinergic vs. Botox Comparison Study
NICHD Pelvic Floor Disorders Network
NCT01166438
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
University of Alabama at Birmingham
NCT01175382
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
MedtronicNeuro
NCT02857816
Bacterial Genomic Sequencing in Overactive Bladder
Loyola University
NCT01642277
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Allergan
NCT00932022
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
University of California, Irvine
NCT05308979
Overactive Bladder Innovative Therapy Trial (OrBIT)
Uroplasty
NCT00448175
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
The Cleveland Clinic
NCT05719285
Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder
University of California, Irvine
NCT01047046
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
VA Office of Research and Development
NCT03149809
Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB
Weill Medical College of Cornell University
NCT03017170
Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
Ethicon Endo-Surgery
NCT01125722
A Pilot Study Evaluating the Usability of the Oabi Mobile Application
Massachusetts General Hospital
NCT04534946
Botulin-A Toxin Instillations and Overactive Bladder
Mayo Clinic
NCT00583219
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
GlaxoSmithKline
NCT00501267
Lessening Incontinence by Learning Yoga
University of California, San Francisco
NCT01672190
Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
University of Rochester
NCT00714792
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
GlaxoSmithKline
NCT00427596
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
Baylor Research Institute
NCT03817931
Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS)
Nine Continents Medical
NCT04115228
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
Pfizer
NCT00220389
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
| Phase 3 | 3 |
| Phase 4 | 12 |
Top Sponsors
Named interventions
Most-linked intervention names on Overactive Bladder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Overactive Bladder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Overactive Bladder page
48 registered trials, 21 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 21 Overactive Bladder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Allergan sponsors the most Overactive Bladder trials on record, review their full trial history before evaluating a specific study. See Allergan's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Overactive Bladder condition card totals 48 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.